Skip to main content
. Author manuscript; available in PMC: 2010 Jul 1.
Published in final edited form as: Cancer Res. 2009 Jun 23;69(13):5450–5457. doi: 10.1158/0008-5472.CAN-08-4031

Figure 4.

Figure 4

MnTE-2-PyP5+ protected H9c2 cardiomyocytes from doxorubicin toxicity. Doxorubicin EC50 measurements of H9c2 cells pretreated with 2.5 or 5 µM MnTE-2-PyP5+ for 2 h, followed by a 48 h doxorubicin treatment. Values represent the mean + S.E.M. (n=3). * denotes significantly different from control (no MnTE-2-PyP5+ cells) (p ≤ 0.05).